EUCTR2007-006338-32-ES进行中（未招募）1 期
Estudio en fase II de búsqueda de dosis, multicéntrico, aleatorio, de grupos paralelos, parcialmente enmascarado, con placebo y Avonex® como fármacos control, para evaluar la eficacia, determinada por las lesiones cerebrales que aparecen en la RMN y la seguridad de dos pautas terapéuticas de ocrelizumab en pacientes con EMRR.Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis
Hoffman La Roche Ltd0 个研究点目标入组 200 人开始时间: 2008年3月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Ability to provide written informed consent and to be compliant with the schedule of protocol assessments;
- •2. RRMS, as defined by the McDonald criteria (2005);
- •3. Ages 18-55 years,
- •4. Evidence of recent MS activity as defined below:
- •a. At least six T2 lesions on an MRI scan done in the year prior to screening, based on local reading. Should an MRI scan be unavailable within the last year or showing less than six T2 lesions, a screening MRI scan with at least six T2 lesions is required for the patient to be eligible, or
- •b. Patient had 2 documented relapses within the year prior to screening;
- •5. EDSS at baseline from 1.0 to 6.0 points;
- •6. At least two documented relapses within the last 3 years prior to screening, at least one of which occurred within the last year prior to screening;
- •7. For sexually active female and male patients of reproductive potential, use of reliable means of contraception as described below:
- •- Two methods of contraception throughout the trial, including the active treatment phase AND for 48 weeks after the last dose of ocrelizumab, or until their B-cells have repleted, whichever is the longer.
- •- Acceptable methods of contraception include one primary (e.g. systemic hormonal contraception or tubal ligation of the female partner, vasectomy of the male partner) AND one secondary barrier method (e.g. latex condoms, spermicide) OR a double barrier method (e.g. latex condom, intrauterine device, vaginal ring or pessary plus spermicide (e.g. foam, vaginal suppository, gel, cream)) may be used.
- •8. For patients of non reproductive potential:
- •a. Women may be enrolled if postmenopausal (i.e. spontaneous amenorrhea for the past year confirmed by an FSH level greater than 40 mIU/mL unless the patient is receiving a hormonal therapy for their menopause or surgically sterile (i.e. hysterectomy, complete bilateral oophorectomy);
- •b. Men may be enrolled if they are surgically sterile.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Secondary or primary progressive MS at screening
- •2. Disease duration > 15 years in patients with an EDSS = 2.0
- •3. Incompatibility with MRI
- •4. Contra-indications to or intolerance of oral or i.v. corticosteroids, including methylprednisolone administered i.v., according to the country label
- •5. Known presence of other neurologic disorders, including but not limited to, the following:
- •- History of ischemic cerebrovascular disorders or ischemia of the spinal cord
- •- History or known presence of CNS or spinal cord tumor, potential metabolic causes of myelopathy, infectious causes of myelopathy, history of genetically inherited progressive CNS degenerative disorder, Neuromyelitis optica, history or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease, history or known presence of sarcoidosis, history of severe, clinically significant brain or spinal cord trauma, history of progressive multifocal leukoencephalopathy
- •Exclusions Related to General Health:
- •1. Pregnancy or lactation
- •2. Lack of peripheral venous access
- •3. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- •4. Significant, uncontrolled disease, such as cardiovascular, cardiac arrhythmia, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine or gastrointestinal
- •5. Congestive heart failure NYHA III or IV functional severity
- •6. Known active bacterial, viral, fungal, mycobacterial infection or other infection [including tuberculosis [TB] or atypical mycobacterial disease (but excluding fungal infection of nail beds)] or any major episode of infection requiring hospitalization or treatment with i.v. antibiotics within 4 weeks prior to screening or oral antibiotics within 2 weeks prior to screening
- •7. History or known presence of recurrent or chronic infection (e.g., hepatitis B or C, HIV, syphilis, tuberculosis)
- •8. History of cancer, including solid tumors and hematological malignancies (except basal cell, in situ squamous cell carcinomas of the skin, and in situ carcinoma of the cervix of the uterus that have been excised and resolved)
- •9. History of alcohol or drug abuse within 24 weeks prior to randomization
- •10. History of or currently active primary or secondary immunodeficiency
- •11. History or laboratory evidence of coagulation disorders
- •Exclusions Related to Medications
- •1. Treatment with any investigational agent within 4 weeks of screening or five half-lives of the investigational drug (whichever is longer)
- •2. Receipt of a live vaccine within 6 weeks prior to randomization
- •Exclusions Related to Medications Potentially Used for the Treatment of MS
- •1. Incompatibility with Avonex use (see protocol)
- •2. Previous treatment with rituximab
- •3. Previous treatment with lymphocyte-depleting therapies (e.g., Campath, anti-CD4, cladribine, cyclophosphamide, total body irradiation, bone marrow transplantation) except mitoxantrone which should not be used within 48 weeks prior to randomization
- •4. Treatment with lymphocyte trafficking blockers (e.g. natalizumab, FTY720) within 24 weeks prior to randomization
- •5. Treatment with beta interferons, glatiramer acetate, i.v. Immunoglobulin (i.v. Ig), plasmapheresis, or immunosuppressive therapies (e.g., mycophenolate mofetil [MMF], cyclosporine or azathioprine) within 12 weeks prior to randomization
- •6. Systemic corticosteroid therapy within 4 weeks prior to randomization
- •Exclusions Related to Laboratory Findi
研究者
相似试验
进行中（未招募）
不适用
Ensayo clínico en fase 2 de búsqueda de dosis, multicéntrico, doble- ciego, aleatorizado y controlado con placebo para investigar la eficacia, seguridad, tolerancia y farmacocinética del inhibidor de la DPP-IV, RO4876904, en pacientes con diabetes tipo 2 (BC20779).Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO4876904 in patients with type 2 diabetesDiabetes Tipo 2MedDRA version: 9.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentEUCTR2007-001257-25-ESF. Hoffmann-La Roche Ltd250
进行中（未招募）
1 期
Estudio fase II, multicéntrico, para evaluar los marcadores predictores de respuesta en cáncerde mama localmente avanzado, tratado con bevacizumab en combinación con quimioterapianeoadyuvante.Cancer Mama localmente avanzadoMedDRA version: 9Level: LLTClassification code 10006187Term: Breast cancerEUCTR2009-011037-27-ESInstituto Científico Tecnológico de Navarra (ICTN)75
进行中（未招募）
不适用
Estudio fase II, multicéntrico para evaluar la eficacia y la seguridad de la administración del esquema COMP-14 (CICLOFOSFAMIDA, VINCRISTINA, DOXORUBICINA LIPOSÓMICA-MYOCET® Y PREDNISONA) combinado con RITUXIMAB en el tratamiento de 1ª línea de pacientes con Linfoma no Hodgkin B agresivo y riesgo cardiovascularinfoma no Hodgkin B agresivo y riesgo cardiovascularMedDRA version: 9.1Level: LLTClassification code 10029593Term: Non-Hodgkin's lymphoma NOSEUCTR2008-002115-41-ESAsociación Dr. Peset para el estudio de la Hematología (ADOPEH).
进行中（未招募）
不适用
Ensayo clínico en fase II, multicéntrico, doble ciego, aleatorizado, de dosis repetitivas, para la determinación de dosis de Alpharadin ™ en el tratamiento de pacientes con cáncer de próstata refractarios al tratamiento hormonal y con metástasis óseas”A double blind, randomised, dose finding, repeat dose, phase II, multicentre study of Alpharadin TM for the treatment of patients with hormone refractory prostate cancer and skeletal metastases.EUCTR2005-003680-22-ESAlgeta ASA117
进行中（未招募）
不适用
A PHASE II EXPLORATORY, ASCENDING DOSE, MULTICENTRE STUDY TOINVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY ANDTOLERABILITY, OF BIM 23A760 IN ACROMEGALIC PATIENTS. - NDAcromegaly.MedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyEUCTR2008-000500-83-ITBEAUFOUR IPSEN PHARMA24